This site is intended for healthcare professionals

Bavencio + axitinib combination accepted for use within NHS Scotland for the first-line treatment of adult patients with advanced renal cell carcinoma. Merck KGaA + Pfizer

Read time: 1 mins
Last updated:13th Oct 2020
Published:13th Oct 2020
Condition: Renal Cell Carcinoma
Type: drug
Register free for full access to